Dr. Rugo on Hormone Therapy for Patients With Breast Cancer

Hope S. Rugo, MD
Published: Monday, Nov 06, 2017



Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.

Oncologists are focusing on trying to find agents that make hormone therapy work better for patients with hormone receptor-positive breast cancer, which may help them further understand latency, explains Rugo.

Ongoing clinical trials looking at adjuvant or post-neoadjuvant treatment with CDK 4/6 inhibitors versus placebo or standard of care will hopefully help oncologists learn more about preventing late recurrences, says Rugo.
SELECTED
LANGUAGE


Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.

Oncologists are focusing on trying to find agents that make hormone therapy work better for patients with hormone receptor-positive breast cancer, which may help them further understand latency, explains Rugo.

Ongoing clinical trials looking at adjuvant or post-neoadjuvant treatment with CDK 4/6 inhibitors versus placebo or standard of care will hopefully help oncologists learn more about preventing late recurrences, says Rugo.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x